Engineered peptides for applications in cancer-targeted drug delivery and tumor detection

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue , 2016, Pages

  Soudy, R ^a,b   Byeon, N ^a   Raghuwanshi, Y ^a   Ahmed, S ^a,e   Lavasanifar, A ^a,c   Kaur, K ^a,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CAIRO UNIVERSITY   (Egypt)

^c Assiut University   (Egypt)

^d CHAPMAN UNIVERSITY   (United States)

^e NONE

Author keywords

Aminopeptidase N; Cancer targeting peptides; Integrins; Phage display; Spot synthesis; Targeted drug delivery; Tumor imaging

Indexed keywords

6 O METHYLGUANINE; AFLIBERCEPT; BRADYKININ; BUFALIN; CELL SURFACE RECEPTOR; CILENGITIDE; CISPLATIN; COPPER 64; DAUNORUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GONADORELIN AGONIST; INTEGRIN; IODINE 125; IODINE 131; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; PACLITAXEL; PEPTIDE; PROTEIN P160; QUANTUM DOT; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; TRIFLUOROETHANOL; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; LIGAND;

ANGIOGENESIS; BINDING AFFINITY; BREAST CANCER; CHEMICAL PHENOMENA; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MOLECULAR WEIGHT; NONHUMAN; PANCREAS CANCER; PHAGE DISPLAY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH; REVIEW; SEQUENCE ANALYSIS; SOLID TUMOR; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; NEOPLASM; PROTEIN ENGINEERING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NEOPLASMS; PEPTIDES; PROTEIN ENGINEERING;

EID: 85010454646     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557516666160219121836     Document Type: Review

References (137)

1. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D.M., Therapeutic Nanoparticles for Drug Delivery in Cancer. Clinical Cancer Research, 2008, 14 (5), 1310-1316.
2. Liang, X.-J.; Chen, C.; Zhao, Y.; Wang, P.C., 2009; Vol. 596, pp 467-488.
3. Aird, W.C., Phenotypic Heterogeneity of the Endothelium. Circulation research, 2007, 100 (2), 174-190.
4. Wang, B.e.a., eds Drug Delivery: Principles and Applications,. Weily, 2005.
5. Ladner, R.C.; Sato, A.K.; Gorzelany, J.; de Souza, M., Phage display-derived peptides as therapeutic alternatives to antibodies. Drug discovery today, 2004, 9 (12), 525-529.
6. Allen, T.M., Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2002, 2 (10), 750-763.
7. Desgrosellier, J.S.; Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer, 2010, 10 (1), 9-22.
8. Dunehoo, A.L.; Anderson, M.; Majumdar, S.; Kobayashi, N.; Berkland, C.; Siahaan, T.J., Cell adhesion molecules for targeted drug delivery. Journal of Pharmaceutical Sciences, 2006, 95 (9), 1856-1872.
9. Avraamides, C.J.; Garmy-Susini, B.; Varner, J.A., Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer, 2008, 8 (8), 604-617.
10. Pierschbacher, M.D.; Ruoslahti, E., Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature, 1984, 309 (5963), 30-33.
11. Ruoslahti, E., The RGD story: a personal account. Matrix Biology, 2003, 22 (6), 459-465.
12. Pierschbacher, M.D.; Ruoslahti, E., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. Journal of Biological Chemistry, 1987, 262 (36), 17294-17298.
13. Danhier, F.; Breton, A.L.; Préat, V., RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis. Molecular Pharmaceutics, 2012, 9 (11), 2961-2973.
14. Mina-Osorio, P., The moonlighting enzyme CD13: old and new functions to target. Trends in Molecular Medicine, 2008, 14 (8), 361-371.
15. Fukasawa, K.; Fujii, H.; Saitoh, Y.; Koizumi, K.; Aozuka, Y.; Sekine, K.; Yamada, M.; Saiki, I.; Nishikawa, K., Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer letters, 2006, 243 (1), 135-143.
16. Corti, A.; Curnis, F.; Arap, W.; Pasqualini, R., The neovasculature homing motif NGR: more than meets the eye. Blood, 2008, 112 (7), 2628-2635.
17. Wickström, M.; Larsson, R.; Nygren, P.; Gullbo, J., Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer science, 2011, 102 (3), 501-508.
18. Curnis, F.; Arrigoni, G.; Sacchi, A.; Fischetti, L.; Arap, W.; Pasqualini, R.; Corti, A., Differential Binding of Drugs Containing the NGR Motif to CD13 Isoforms in Tumor Vessels, Epithelia, and Myeloid Cells. Cancer research, 2002, 62 (3), 867-874.
19. Toyoda, H.; Komurasaki, T.; Uchida, D.; Takayama, Y.; Isobe, T.; Okuyama, T.; Hanada, K., Epiregulin: a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. Journal of Biological Chemistry, 1995, 270 (13), 7495-7500.
20. Groenen LC, N.E., Burgess AW., Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors, 1994, 11 (4), 235-257.
21. Yewale, C.; Baradia, D.; Vhora, I.; Patil, S.; Misra, A., Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013, 34 (34), 8690-8707.
22. Song, S.; Liu, D.; Peng, J.; Deng, H.; Guo, Y.; Xu, L.X.; Miller, A.D.; Xu, Y., Novel peptide ligand directs liposomes toward EGF R high-expressing cancer cells in vitro and in vivo. The FASEB Journal, 2009, 23 (5), 1396-1404.
23. Schäfer A, P.A., Schaffert D, van Weerden WM, de Ridder CM, Rödl W, Vetter A, Spitzweg C, Kraaij R, Wagner E, Ogris M., Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFRtargeted gene transfer system avoiding receptor activation. Hum Gene Ther, 2011, 22 (12), 1463-1473.
24. Capello, A.; Krenning, E.P.; Bernard, B.F.; Breeman, W.A.P.; van Hagen, M.P.; de Jong, M., Increased Cell Death After Therapy with an Arg-Gly-Asp-Linked Somatostatin Analog. Journal of Nuclear Medicine, 2004, 45 (10), 1716-1720.
25. Zhang, X.; Cai, W.; Cao, F.; Schreibmann, E.; Wu, Y.; Wu, J.C.; Xing, L.; Chen, X., 18F-Labeled Bombesin Analogs for Targeting GRP Receptor-Expressing Prostate Cancer. Journal of Nuclear Medicine, 2006, 47 (3), 492-501.
26. Stewart, J.M.; Gera, L.; Chan, D.C.; York, E.J.; Simkeviciene, V.; Bunn Jr, P.A.; Taraseviciene-Stewart, L., Combination cancer chemotherapy with one compound: Pluripotent bradykinin antagonists. Peptides, 2005, 26 (8), 1288-1291.
27. Lam, K.S.; Salmon, S.E.; Hersh, E.M.; Hruby, V.J.; Kazmierski, W.M.; Knapp, R.J., A new type of synthetic peptide library for identifying ligand-binding activity. Nature, 1991, 354 (6348), 82-84.
28. Lam, K.S.; Lebl, M.; Krchňák, V., The “One-Bead-One-Compound” Combinatorial Library Method. Chemical reviews, 1997, 97 (2), 411-448.
29. Frank, R., Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron, 1992, 48 (42), 9217-9232.
30. Smith, G.P., Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface. Science, 1985, 228 (4705), 1315-1317.
31. Krag, D.N.; Shukla, G.S.; Shen, G.-P.; Pero, S.; Ashikaga, T.; Fuller, S.; Weaver, D.L.; Burdette-Radoux, S.; Thomas, C., Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries. Cancer research, 2006, 66 (15), 7724-7733.
32. Samoylova TI, M.N., Globa LP, Cox NR, Peptide phage display: opportunities for development of personalized anti-cancer strategies. Anti-cancer agents in medicinal chemistry, 2006, 6 (1), 9-17.
33. Lauren RH Krumpe, T.M., Potential of phage-displayed peptide library technology to identify functional targeting peptides. Expert Opin Drug Discov, 2007, 2 (4), 525-537.
34. Arap, W.; Pasqualini, R.; Ruoslahti, E., Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science, 1998, 279 (5349), 377-380.
35. Aina, O.H.; Liu, R.; Sutcliffe, J.L.; Marik, J.; Pan, C.-X.; Lam, K.S., From Combinatorial Chemistry to Cancer-Targeting Peptides. Molecular Pharmaceutics, 2007, 4 (5), 631-651.
36. Kappel, J.C.; Fan, Y.C.; Lam, K.S. Valle, S.D.; Escher, E.; Lubell, W.D., Eds.; Springer New York, 2009; Vol. 611, pp 21-22.
37. Winkler DF, A.H., Hilpert K., SPOT synthesis as a tool to study protein-protein interactions. Methods Mol Biol, 2011, 723 (105-127).
38. Ahmed, S.; Mathews, A.S.; Byeon, N.; Lavasanifar, A.; Kaur, K., Peptide Arrays for Screening Cancer Specific Peptides. Analytical chemistry, 2010, 82 (18), 7533-7541.
39. Soudy, R.; Wang, L.; Kaur, K., Synthetic peptides derived from the sequence of a lasso peptide microcin J25 show antibacterial activity. Bioorganic and Medicinal Chemistry, 2012, 20 (5), 1794-1800.
40. Kapoor, P.; Singh, H.; Gautam, A.; Chaudhary, K.; Kumar, R.; Raghava, G.P.S., TumorHoPe: A Database of Tumor Homing Peptides. PloS one, 2012, 7 (4), e35187.
41. Shadidi, M.; Sioud, M., Selective targeting of cancer cells using synthetic peptides. Drug Resistance Updates, 2003, 6 (6), 363-371.
42. Zhang, J.; Spring, H.; Schwab, M., Neuroblastoma tumor cellbinding peptides identified through random peptide phage display. Cancer letters, 2001, 171 (2), 153-164.
43. Askoxylakis, V.; Mier, W.; Zitzmann, S.; Ehemann, V.; Zhang, J.; Kramer, S.; Beck, C.; Schwab, M.; Eisenhut, M.; Haberkorn, U., Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, 47 (6), 981-988.
44. Soudy, R.; Gill, A.; Sprules, T.; Lavasanifar, A.; Kaur, K., Proteolytically Stable Cancer Targeting Peptides with High Affinity for Breast Cancer Cells. Journal of medicinal chemistry, 2011, 54 (21), 7523-7534.
45. Sarangthem, V.; Cho, E.A.; Bae, S.M.; Singh, T.D.; Kim, S.J.; Kim, S.; Jeon, W.B.; Lee, B.H.; Park, R.W., Construction and application of elastin like polypeptide containing IL-4 receptor targeting peptide. PloS one, 2013, 8 (12), e81891.
46. Lu, R.M.; Chen, M.S.; Chang, D.K.; Chiu, C.Y.; Lin, W.C.; Yan, S.L.; Wang, Y.P.; Kuo, Y.S.; Yeh, C.Y.; Lo, A.; Wu, H.C., Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging. PloS one, 2013, 8 (6), e66128.
47. Zitzmann, S.; Mier, W.; Schad, A.; Kinscherf, R.; Askoxylakis, V.; Krämer, S.; Altmann, A.; Eisenhut, M.; Haberkorn, U., A New Prostate Carcinoma Binding Peptide (DUP-1) for Tumor Imaging and Therapy. Clinical Cancer Research, 2005, 11 (1), 139-146.
48. Askoxylakis, V.; Zitzmann-Kolbe, S.; Zoller, F.; Altmann, A.; Markert, A.; Rana, S.; Marr, A.; Mier, W.; Debus, J.; Haberkorn, U., Challenges in Optimizing a Prostate Carcinoma Binding Peptide, Identified through the Phage Display Technology. Molecules, 2011, 16 (2), 1559-1578.
49. Li Z, Z.R., Wu X, Sun Y, Yao M, Li J, Xu Y, Gu J., Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB Journal, 2005, 19 (14), 1978-1985.
50. Du B, Q.M., Zhou Z, Wang P, Wang L, Zhang X, Wu M, Zhang P, Mei B, In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library. Biochem Biophys Res Commun., 2006, 342 (3), 956-962.
51. Du, B.; Han, H.; Wang, Z.; Kuang, L.; Wang, L.; Yu, L.; Wu, M.; Zhou, Z.; Qian, M., targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide. Molecular cancer research : MCR, 2010, 8 (2), 135-144.
52. Tanaka, S.; Pero, S.C.; Taguchi, K.; Shimada, M.; Mori, M.; Krag, D.N.; Arii, S., Specific Peptide Ligand for Grb7 Signal Transduction Protein and Pancreatic Cancer Metastasis. Journal of the National Cancer Institute, 2006, 98 (7), 491-498.
53. Pero, S.C.; Oligino, L.; Daly, R.J.; Soden, A.L.; Liu, C.; Roller, P.P.; Li, P.; Krag, D.N., Identification of Novel Nonphosphorylated Ligands, Which Bind Selectively to the SH2 Domain of Grb7. Journal of Biological Chemistry, 2002, 277 (14), 11918-11926.
54. Huang, C.; Liu, X.Y.; Rehemtulla, A.; Lawrence, T.S., Identification of peptides that bind to irradiated pancreatic tumor cells. International journal of radiation oncology, biology, physics, 2005, 62 (5), 1497-1503.
55. Akita, N.; Maruta, F.; Seymour, L.W.; Kerr, D.J.; Parker, A.L.; Asai, T.; Oku, N.; Nakayama, J.; Miyagawa, S., Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer science, 2006, 97 (10), 1075-1081.
56. Fukumura, D.; Jain, R.K., Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. Journal of cellular biochemistry, 2007, 101 (4), 937-949.
57. Ruoslahti, E., Vascular zip codes in angiogenesis and metastasis. Biochem. Soc. Trans., 2004, 32 (397-402).
58. Boehm, T.; Folkman, J.; Browder, T.; O'Reilly, M.S., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 1997, 390 (6658), 404-407.
59. Browder, T.; Butterfield, C.E.; Kräling, B.M.; Shi, B.; Marshall, B.; O’Reilly, M.S.; Folkman, J., Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drugresistant Cancer. Cancer research, 2000, 60 (7), 1878-1886.
60. Pasqualini, R.; Koivunen, E.; Ruoslahti, E., [alpha]v Integrins as receptors for tumor targeting by circulating ligands. Nat Biotech, 1997, 15 (6), 542-546.
61. Koivunen, E.; Gay, D.A.; Ruoslahti, E., Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. Journal of Biological Chemistry, 1993, 268 (27), 20205-20210.
62. Koivunen E, W.B., Ruoslahti E., Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGDdirected integrins. Biotechnology (N Y), 1995, 13 (3), 265-270.
63. Maubant, S.; Saint-Dizier, D.; Boutillon, M.; Perron-Sierra, F.; Casara, P.J.; Hickman, J.A.; Tucker, G.C.; Van Obberghen Schilling, E., Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood, 2006, 108 (9), 3035-3044.
64. Dickerson, E.B.; Akhtar, N.; Steinberg, H.; Wang, Z.-Y.; Lindstrom, M.J.; Padilla, M.L.; Auerbach, R.; Helfand, S.C., Enhancement of the Antiangiogenic Activity of Interleukin-12 by Peptide Targeted Delivery of the Cytokine to αvβ3 Integrin. Molecular Cancer Research, 2004, 2 (12), 663-673.
65. Burkhart, D.J.; Kalet, B.T.; Coleman, M.P.; Post, G.C.; Koch, T.H., Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Molecular cancer therapeutics, 2004, 3 (12), 1593-1604.
66. Chinot, O.L., Cilengitide in glioblastoma: when did it fail? The Lancet Oncology, 2014, 15 (10), 1044-1045.
67. Xiong JP, S.T., Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA., Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science, 2002, 296 (5565), 151-155.
68. Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S.L.; Jonczyk, A.; Kessler, H., Structural and Functional Aspects of RGDContaining Cyclic Pentapeptides as Highly Potent and Selective Integrin αVβ3 Antagonists. Journal of the American Chemical Society, 1996, 118 (32), 7461-7472.
69. Liu, S., Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging. Molecular Pharmaceutics, 2006, 3 (5), 472-487.
70. Li, Z.-b.; Cai, W.; Cao, Q.; Chen, K.; Wu, Z.; He, L.; Chen, X., 64Cu-Labeled Tetrameric and Octameric RGD Peptides for Small-Animal PET of Tumor αvβ3 Integrin Expression. Journal of Nuclear Medicine, 2007, 48 (7), 1162-1171.
71. Mammen M, C.S.-K., Whitesides GM., Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. Angew. Chem., 1998, 37 (20), 2754-2794.
72. Kubas, H.; Schäfer, M.; Bauder-Wüst, U.; Eder, M.; Oltmanns, D.; Haberkorn, U.; Mier, W.; Eisenhut, M., Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding. Nuclear medicine and biology, 2010, 37 (8), 885-891.
73. Boturyn, D.; Coll, J.-L.; Garanger, E.; Favrot, M.-C.; Dumy, P., Template Assembled Cyclopeptides as Multimeric System for Integrin Targeting and Endocytosis. Journal of the American Chemical Society, 2004, 126 (18), 5730-5739.
74. Falciani, C.; Pini, A.; Bracci, L., Oligo-branched peptides for tumor targeting: from magic bullets to magic forks. Expert opinion on biological therapy, 2009, 9 (2), 171-178.
75. Teesalu, T.; Sugahara, K.N.; Kotamraju, V.R.; Ruoslahti, E., C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proceedings of the National Academy of Sciences, 2009, 106 (38), 16157-16162.
76. Teesalu, T.; Sugahara, K.N.; Ruoslahti, E., Tumor penetrating peptides. Frontiers in oncology, 2013, 3
77. Mamluk, R.; Klagsbrun, M.; Detmar, M.; Bielenberg, D., Soluble neuropilin targeted to the skin inhibits vascular permeability. Angiogenesis, 2005, 8 (3), 217-227.
78. Wise, L.M.; Veikkola, T.; Mercer, A.A.; Savory, L.J.; Fleming, S.B.; Caesar, C.; Vitali, A.; Makinen, T.; Alitalo, K.; Stacker, S.A., Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96 (6), 3071-3076.
79. Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Greenwald, D.R.; Ruoslahti, E., Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs. Science, 2010, 328 (5981), 1031-1035.
80. van Hensbergen, Y.; Broxterman, H.J.; Elderkamp, Y.W.; Lankelma, J.; Beers, J.C.C.; Heijn, M.; Boven, E.; Hoekman, K.; Pinedo, H.M., A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochemical pharmacology, 2002, 63 (5), 897-908.
81. Ndinguri, M.W.; Solipuram, R.; Gambrell, R.P.; Aggarwal, S.; Hammer, R.P., Peptide Targeting of Platinum Anti-Cancer Drugs. Bioconjugate chemistry, 2009, 20 (10), 1869-1878.
82. Ellerby, H.M.; Arap, W.; Ellerby, L.M.; Kain, R.; Andrusiak, R.; Rio, G.D.; Krajewski, S.; Lombardo, C.R.; Rao, R.; Ruoslahti, E.; Bredesen, D.E.; Pasqualini, R., Anti-cancer activity of targeted proapoptotic peptides. Nature medicine, 1999, 5 (9), 1032-1038.
83. Curnis, F.; Sacchi, A.; Borgna, L.; Magni, F.; Gasparri, A.; Corti, A., Enhancement of tumor necrosis factor [alpha] antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotech, 2000, 18 (11), 1185-1190.
84. Santoro, A.; Pressiani, T.; Citterio, G.; Rossoni, G.; Donadoni, G.; Pozzi, F.; Rimassa, L.; Personeni, N.; Bozzarelli, S.; Colombi, S.; De Braud, F.G.; Caligaris-Cappio, F.; Lambiase, A.; Bordignon, C., Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. British journal of cancer, 2010, 103 (6), 837-844.
85. Santoro, A.; Rimassa, L.; Sobrero, A.F.; Citterio, G.; Sclafani, F.; Carnaghi, C.; Pessino, A.; Caprioni, F.; Andretta, V.; Tronconi, M.C.; Finocchiaro, G.; Rossoni, G.; Zanoni, A.; Miggiano, C.; Rizzardi, G.-P.; Traversari, C.; Caligaris-Cappio, F.; Lambiase, A.; Bordignon, C., Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. European Journal of Cancer, 2010, 46 (15), 2746-2752.
86. Negussie, A.H.; Miller, J.L.; Reddy, G.; Drake, S.K.; Wood, B.J.; Dreher, M.R., Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. Journal of Controlled Release, 2010, 143 (2), 265-273.
87. Metaferia, B.B.; Rittler, M.; Gheeya, J.S.; Lee, A.; Hempel, H.; Plaza, A.; Stetler-Stevenson, W.G.; Bewley, C.A.; Khan, J., Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry. Bioorganic and Medicinal Chemistry Letters, 2010, 20 (24), 7337-7340.
88. Colombo, G.; Curnis, F.; De Mori, G.M.S.; Gasparri, A.; Longoni, C.; Sacchi, A.; Longhi, R.; Corti, A., Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif. Journal of Biological Chemistry, 2002, 277 (49), 47891-47897.
89. Plesniak, L.A.; Salzameda, B.; Hinderberger, H.; Regan, E.; Kahn, J.; Mills, S.A.; Teriete, P.; Yao, Y.; Jennings, P.; Marassi, F.; Adams, J.A., Structure and Activity of CPNGRC: A Modified CD13/APN Peptidic Homing Motif. Chemical biology and drug design, 2010, 75 (6), 551-562.
90. Curnis, F.; Longhi, R.; Crippa, L.; Cattaneo, A.; Dondossola, E.; Bachi, A.; Corti, A., Spontaneous Formation of L-Isoaspartate and Gain of Function in Fibronectin. Journal of Biological Chemistry, 2006, 281 (47), 36466-36476.
91. Curnis, F.; Cattaneo, A.; Longhi, R.; Sacchi, A.; Gasparri, A.M.; Pastorino, F.; Di Matteo, P.; Traversari, C.; Bachi, A.; Ponzoni, M.; Rizzardi, G.-P.; Corti, A., Critical Role of Flanking Residues in NGR-to-isoDGR Transition and CD13/Integrin Receptor Switching. Journal of Biological Chemistry, 2010, 285 (12), 9114-9123.
92. Soudy, R.; Ahmed, S.; Kaur, K., NGR Peptide Ligands for Targeting CD13/APN Identified through Peptide Array Screening Resemble Fibronectin Sequences. ACS Combinatorial Science, 2012.
93. Laakkonen, P.; Åkerman, M.E.; Biliran, H.; Yang, M.; Ferrer, F.; Karpanen, T.; Hoffman, R.M.; Ruoslahti, E., Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101 (25), 9381-9386.
94. Laakkonen, P.; Zhang, L.; Ruoslahti, E., Peptide Targeting of Tumor Lymph Vessels. Annals of the New York Academy of Sciences, 2008, 1131 (1), 37-43.
95. Laakkonen, P.; Porkka, K.; Hoffman, J.A.; Ruoslahti, E., A tumorhoming peptide with a targeting specificity related to lymphatic vessels. Nature medicine, 2002, 8 (7), 751-755.
96. Fogal, V.; Zhang, L.; Krajewski, S.; Ruoslahti, E., Mitochondrial/Cell-Surface Protein p32/gC1qR as a Molecular Target in Tumor Cells and Tumor Stroma. Cancer research, 2008, 68 (17), 7210-7218.
97. Witt, H.; Hajdin, K.; Iljin, K.; Greiner, O.; Niggli, F.K.; Schäfer, B.W.; Bernasconi, M., Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1. International Journal of Cancer, 2009, 124 (9), 2026-2032.
98. Zhang, L.; Giraudo, E.; Hoffman, J.A.; Hanahan, D.; Ruoslahti, E., Lymphatic Zip Codes in Premalignant Lesions and Tumors. Cancer research, 2006, 66 (11), 5696-5706
99. Ruoslahti, E.; Bhatia, S.N.; Sailor, M.J., Targeting of drugs and nanoparticles to tumors. The Journal of cell biology, 2010, 188 (6), 759-768.
100. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O.C., Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Advanced drug delivery reviews, 2014, 66 2-25.
101. Laakkonen, P.; Vuorinen, K., Homing peptides as targeted delivery vehicles. Integrative Biology, 2010, 2 (7-8), 326-337.
102. Nagy, A.; Schally, A.V.; Armatis, P.; Szepeshazi, K.; Halmos, G.; Kovacs, M.; Zarandi, M.; Groot, K.; Miyazaki, M.; Jungwirth, A.; Horvath, J., Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proceedings of the National Academy of Sciences, 1996, 93 (14), 7269-7273.
103. Kurzrock, R.; Gabrail, N.; Chandhasin, C.; Moulder, S.; Smith, C.; Brenner, A.; Sankhala, K.; Mita, A.; Elian, K.; Bouchard, D.; Sarantopoulos, J., Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors. Molecular cancer therapeutics, 2012, 11 (2), 308-316.
104. Soudy, R.; Chen, C.; Kaur, K., Novel Peptide-Doxorubucin Conjugates for Targeting Breast Cancer Cells Including the Multidrug Resistant Cells. Journal of medicinal chemistry, 2013, 56 (19), 7564-7573.
105. Callahan, R., Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer. Journal of the advanced practitioner in oncology, 2014, 5 (2), 134-139.
106. Matsui, H.; Takeshita, A.; Naito, K.; Shinjo, K.; Shigeno, K.; Maekawa, M.; Yamakawa, Y.; Tanimoto, M.; Kobayashi, M.; Ohnishi, K.; Ohno, R., Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia, 2002, 16 (5), 813-819.
107. Takeshita, A.; Shinjo, K.; Yamakage, N.; Ono, T.; Hirano, I.; Matsui, H.; Shigeno, K.; Nakamura, S.; Tobita, T.; Maekawa, M.; Ohnishi, K.; Sugimoto, Y.; Kiyoi, H.; Naoe, T.; Ohno, R., CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with Bcell chronic lymphocytic leukaemia and lymphoma. British Journal of Haematology, 2009, 146 (1), 34-43.
108. Kovtun, Y.V.; Audette, C.A.; Mayo, M.F.; Jones, G.E.; Doherty, H.; Maloney, E.K.; Erickson, H.K.; Sun, X.; Wilhelm, S.; Ab, O.; Lai, K.C.; Widdison, W.C.; Kellogg, B.; Johnson, H.; Pinkas, J.; Lutz, R.J.; Singh, R.; Goldmacher, V.S.; Chari, R.V.J., Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance. Cancer research, 2010, 70 (6), 2528-2537.
109. Yu, B.; Tai, H.C.; Xue, W.; Lee, L.J.; Lee, R.J., Receptor-targeted nanocarriers for therapeutic delivery to cancer. Molecular membrane biology, 2010, 27 (7), 286-298.
110. Pearce, T.R.; Shroff, K.; Kokkoli, E., Peptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery. Advanced Materials, 2012, 24 (28), 3803-3822.
111. Xiong, X.-B.; Ma, Z.; Lai, R.; Lavasanifar, A., The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials, 2010, 31 (4), 757-768.
112. Pastorino, F.; Brignole, C.; Di Paolo, D.; Nico, B.; Pezzolo, A.; Marimpietri, D.; Pagnan, G.; Piccardi, F.; Cilli, M.; Longhi, R.; Ribatti, D.; Corti, A.; Allen, T.M.; Ponzoni, M., Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy. Cancer research, 2006, 66 (20), 10073-10082.
113. Shahin, M.; Ahmed, S.; Kaur, K.; Lavasanifar, A., Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel. Biomaterials, 2011, 32 (22), 5123-5133.
114. Shahin, M.; Soudy, R.; El-Sikhry, H.; Seubert, J.M.; Kaur, K.; Lavasanifar, A., Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin. Cancer letters, 2012.
115. Shahin, M.; Soudy, R.; Aliabadi, H.M.; Kneteman, N.; Kaur, K.; Lavasanifar, A., Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity. Biomaterials, 2013, 34 (16), 4089-4097.
116. Heppeler, A.; Froidevaux, S.; Eberle, A.N.; Maecke, H.R., Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides. Current medicinal chemistry, 2000, 7 (9), 971-994.
117. Åkerman, M.E.; Chan, W.C.W.; Laakkonen, P.; Bhatia, S.N.; Ruoslahti, E., Nanocrystal targeting in vivo. Proceedings of the National Academy of Sciences, 2002, 99 (20), 12617-12621.
118. Rufini, V.; Calcagni, M.L.; Baum, R.P., Imaging of Neuroendocrine Tumors. Seminars in nuclear medicine, 2006, 36 (3), 228-247.
119. Scopinaro, F.; Vincentis, G.; Varvarigou, A.; Laurenti, C.; Iori, F.; Remediani, S.; Chiarini, S.; Stella, S., 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. European journal of nuclear medicine and molecular imaging, 2003, 30 (10), 1378-1382.
120. Fani, M.; Maecke, H.R.; Okarvi, S.M., Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics, 2012, 2 (5), 481-501.
121. Lee, H.-Y.; Li, Z.; Chen, K.; Hsu, A.R.; Xu, C.; Xie, J.; Sun, S.; Chen, X., PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)-Conjugated Radiolabeled Iron Oxide Nanoparticles. Journal of Nuclear Medicine, 2008, 49 (8), 1371-1379.
122. Mulder, W.J.M.; Strijkers, G.J.; Habets, J.W.; Bleeker, E.J.W.; van der Schaft, D.W.J.; Storm, G.; Koning, G.A.; Griffioen, A.W.; Nicolay, K., MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. The FASEB Journal, 2005, 19 (14), 2008-2010.
123. Zhou, Y.; Chakraborty, S.; Liu, S., Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics, 2011, 1 58-82.
124. Buehler, A.; van Zandvoort, M.A.M.J.; Stelt, B.J.; Hackeng, T.M.; Schrans-Stassen, B.H.G.J.; Bennaghmouch, A.; Hofstra, L.; Cleutjens, J.P.M.; Duijvestijn, A.; Smeets, M.B.; de Kleijn, D.P.V.; Post, M.J.; de Muinck, E.D., cNGR: A Novel Homing Sequence for CD13/APN Targeted Molecular Imaging of Murine Cardiac Angiogenesis In Vivo. Arteriosclerosis, thrombosis, and vascular biology, 2006, 26 (12), 2681-2687.
125. Liu, P.; Qin, L.; Wang, Q.; Sun, Y.; Zhu, M.; Shen, M.; Duan, Y., cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer. Biomaterials, 2012, 33 (28), 6739-6747.
126. Yin, P.; Wang, Y.; Qiu, Y.; Hou, L.; Liu, X.; Qin, J.; Duan, Y.; Liu, P.; Qiu, M.; Li, Q., Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. International journal of nanomedicine, 2012, 7 3961-3969.
127. Miura, Y.; Takenaka, T.; Toh, K.; Wu, S.; Nishihara, H.; Kano, M.R.; Ino, Y.; Nomoto, T.; Matsumoto, Y.; Koyama, H.; Cabral, H.; Nishiyama, N.; Kataoka, K., Cyclic RGD-Linked Polymeric Micelles for Targeted Delivery of Platinum Anticancer Drugs to Glioblastoma through the Blood-Brain Tumor Barrier. ACS Nano, 2013, 7 (10), 8583-8592.
128. Chen, Z.; Deng, J.; Zhao, Y.; Tao, T., Cyclic RGD peptidemodified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. International journal of nanomedicine, 2012, 7 3803-3811.
129. Luo, L.-M.; Huang, Y.; Zhao, B.-X.; Zhao, X.; Duan, Y.; Du, R.; Yu, K.-F.; Song, P.; Zhao, Y.; Zhang, X.; Zhang, Q., Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials, 2013, 34 (4), 1102-1114.
130. Zhao, B.-J.; Ke, X.-Y.; Huang, Y.; Chen, X.-M.; Zhao, X.; Zhao, B.-X.; Lu, W.-l.; Lou, J.-N.; Zhang, X.; Zhang, Q., The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. Journal of Drug Targeting, 2011, 19 (5), 382-390.
131. Notni, J.; Pohle, K.; Wester, H.-J., Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of 68Ga-TRAP(RGD)3. Nuclear medicine and biology, 2013, 40 (1), 33-41.
132. Yang, J.; Luo, Y.; Xu, Y.; Li, J.; Zhang, Z.; Wang, H.; Shen, M.; Shi, X.; Zhang, G., Conjugation of Iron Oxide Nanoparticles with RGD-Modified Dendrimers for Targeted Tumor MR Imaging. ACS applied materials and interfaces, 2015, 7 (9), 5420-5428.
133. Šimeček, J.; Notni, J.; Kapp, T.G.; Kessler, H.; Wester, H.-J., Benefits of NOPO As Chelator in Gallium-68 Peptides, Exemplified by Preclinical Characterization of 68Ga-NOPO-c(RGDfK). Molecular Pharmaceutics, 2014, 11 (5), 1687-1695.
134. Sun, X.; Huang, X.; Yan, X.; Wang, Y.; Guo, J.; Jacobson, O.; Liu, D.; Szajek, L.P.; Zhu, W.; Niu, G.; Kiesewetter, D.O.; Sun, S.; Chen, X., Chelator-Free 64Cu-Integrated Gold Nanomaterials for Positron Emission Tomography Imaging Guided Photothermal Cancer Therapy. ACS Nano, 2014, 8 (8), 8438-8446.
135. Maschauer, S.; Haubner, R.; Kuwert, T.; Prante, O., 18F-Glyco-RGD Peptides for PET Imaging of Integrin Expression: Efficient Radiosynthesis by Click Chemistry and Modulation of Biodistribution by Glycosylation. Molecular Pharmaceutics, 2014, 11 (2), 505-515.
136. Chen, K.; Ma, W.; Li, G.; Wang, J.; Yang, W.; Yap, L.-P.; Hughes, L.D.; Park, R.; Conti, P.S., Synthesis and Evaluation of 64Cu-Labeled Monomeric and Dimeric NGR Peptides for MicroPET Imaging of CD13 Receptor Expression. Molecular Pharmaceutics, 2013, 10 (1), 417-427.
137. Máté, G.; Kertész, I.; Enyedi, K.N.; Mező, G.; Angyal, J.; Vasas, N.; Kis, A.; Szabó, É.; Emri, M.; Bíró, T.; Galuska, L.; Trencsényi, G., In vivo imaging of Aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer 68Ga-NOTA-c(NGR). European Journal of Pharmaceutical Sciences, 2015, 69 (0), 61-71.